Citadel Advisors’s XBiotech XBIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-42,816
Closed -$106K 14260
2025
Q3
$114K Buy
42,816
+10,333
+32% +$30.6K ﹤0.01% 11753
2025
Q2
$96.5K Buy
+32,483
New +$94.4K ﹤0.01% 11382
2025
Q1
Sell
-13
Closed -$51 15709
2024
Q4
$51 Buy
+13
New +$89 ﹤0.01% 14391
2024
Q3
Sell
-4,890
Closed -$25.1K 15379
2024
Q2
$25.1K Sell
4,890
-2,152
-31% -$16.6K ﹤0.01% 12434
2024
Q1
$57.3K Sell
7,042
-5,232
-43% -$30K ﹤0.01% 12045
2023
Q4
$49.1K Buy
12,274
+1,621
+15% +$6.46K ﹤0.01% 11796
2023
Q3
$43.9K Sell
10,653
-5,946
-36% -$29.8K ﹤0.01% 11899
2023
Q2
$98.6K Sell
16,599
-3,775
-19% -$17K ﹤0.01% 10964
2023
Q1
$70.3K Buy
20,374
+8,649
+74% +$32.2K ﹤0.01% 11725
2022
Q4
$41.2K Buy
+11,725
New +$40K ﹤0.01% 12376
2022
Q3
Sell
-80,884
Closed -$455K 13734
2022
Q2
$455K Buy
80,884
+39,615
+96% +$267K ﹤0.01% 8855
2022
Q1
$356K Buy
+41,269
New +$414K ﹤0.01% 10189
2021
Q4
Sell
-47,828
Closed -$619K 14881
2021
Q3
$619K Buy
+47,828
New +$762K ﹤0.01% 9358
2020
Q4
Sell
-11,467
Closed -$211K 11605
2020
Q3
$219K Buy
+11,467
New +$198K ﹤0.01% 8667
2020
Q2
Sell
-34,134
Closed -$363K 10609
2020
Q1
$363K Buy
+34,134
New +$556K ﹤0.01% 6990
2019
Q3
Sell
-19,227
Closed -$146K 9829
2019
Q2
$146K Buy
+19,227
New +$167K ﹤0.01% 8371
2017
Q3
Sell
-19,661
Closed -$92.8K 8130
2017
Q2
$92K Buy
+19,661
New +$188K ﹤0.01% 6939

Other funds holding XBIT

Citadel Advisors's XBIT Position: Q4 2025 in Review

Citadel Advisors sold out of XBiotech (XBIT) in Q4 2025, closing a stake of 42,816 shares — an estimated $106K sold.

Citadel Advisors first reported a position in XBIT in Q2 2017 and held it in 17 quarters. The position peaked at $619K in Q3 2021. 41 funds tracked by Wall St. Rank hold XBIT as of Q4 2025.

  • Citadel Advisors reported no remaining XBiotech position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 42,816 XBiotech shares in Q4 2025, an estimated $106K.
  • Citadel Advisors first reported a position in XBiotech in Q2 2017 and held it in 17 quarters.
  • Citadel Advisors's XBiotech position peaked at $619K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held XBiotech as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.